Drug news
Mallinckrodt files MNK 795 at FDA for Pain
Depomed, Inc. announced that the FDA has accepted for filing a New Drug Application (NDA) from Mallinckrodt for MNK-795.
MNK-795 is a controlled-release oral formulation of oxycodone and acetaminophen that has been studied for the management of moderate to severe Acute Pain where the use of an opioid analgesic is appropriate. MNK-795 is formulated with Depomed's Acuform drug delivery technology. The FDA granted the NDA a priority review.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.